{"id":3610,"date":"2020-10-14T05:30:40","date_gmt":"2020-10-14T09:30:40","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\/"},"modified":"2026-09-24T00:08:39","modified_gmt":"2026-09-24T04:08:39","slug":"gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/14\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\/","title":{"rendered":"GenSight Biologics nomme Elsy Boglioli \u00e0 son Conseil d\u2019administration"},"content":{"rendered":"\nParis, France, le 14 octobre 2020, 7h30 CEST<\/strong> \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN\u00a0: FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui\u00a0la nomination d\u2019Elsy Boglioli \u00e0 son Conseil d\u2019administration, en remplacement de Bpifrance Participations. Mme Boglioli rejoint le Conseil en qualit\u00e9 d\u2019administrateur ind\u00e9pendant.\n\n\u00ab\u00a0Je suis particuli\u00e8rement ravie de rejoindre l’\u00e9quipe GenSight au moment o\u00f9 la soci\u00e9t\u00e9 vient de d\u00e9poser une demande d’autorisation de mise sur le march\u00e9 en Europe pour LUMEVOQ, son principal produit pour le traitement de la NOHL,\u00a0\u00bb <\/em>d\u00e9clare Elsy Boglioli<\/strong>. \u00ab\u00a0J’ai h\u00e2te de travailler avec l’\u00e9quipe de direction et le Conseil d’administration afin de mettre, d\u00e8s que possible, ce produit \u00e0 la disposition des patients en attente d\u2019un traitement, et ce dans plusieurs r\u00e9gions du monde \u2013 contribuant ainsi \u00e0 la croissance de l\u2019entreprise et \u00e0 sa transformation.\u00a0\u00bb<\/em>\n\nElsy est fondatrice et Directrice G\u00e9n\u00e9rale de Bio-Up, une soci\u00e9t\u00e9 de conseil en sant\u00e9 qui accompagne des entreprises dans leurs phases de forte croissance ou de transformation, principalement dans le domaine des th\u00e9rapies cellulaire et g\u00e9nique. Elle poss\u00e8de une large expertise et un vaste r\u00e9seau au sein de l\u2019industrie pharmaceutique et des technologies m\u00e9dicales\n\nAvant de cr\u00e9er Bio-Up, Elsy \u00e9tait Vice-pr\u00e9sidente Ex\u00e9cutive, Directrice des Op\u00e9rations de Cellectis, une soci\u00e9t\u00e9 fran\u00e7aise de biotechnologie sp\u00e9cialis\u00e9e dans l\u2019ing\u00e9nierie des g\u00e9nomes et ses applications en oncologie. Chez Cellectis, elle a dirig\u00e9 diverses fonctions strat\u00e9giques et op\u00e9rationnelles : strat\u00e9gie, d\u00e9veloppement commercial, gestion de programmes d’essais cliniques, ainsi que la fabrication, avec pour objectif de renforcer les capacit\u00e9s en interne. Avant de rejoindre Cellectis, Elsy a travaill\u00e9 au Boston Consulting Group (BCG) pendant 12 ans, en tant que Directrice Associ\u00e9e au bureau de Paris, responsable du secteur des biotechnologies pour l\u2019Europe. Elle a travaill\u00e9 en \u00e9troite collaboration avec des soci\u00e9t\u00e9s biotechnologiques et pharmaceutiques sur des sujets tels que l’optimisation du lancement de produits sp\u00e9cialis\u00e9s, les partenariats et les fusions et acquisitions.\n\nElsy est dipl\u00f4m\u00e9e de l\u2019Ecole Polytechnique \u00e0 Paris, et titulaire d\u2019une ma\u00eetrise en \u00e9conomie et gestion de l\u2019Universit\u00e9 Pompeu Fabra<\/em> de Barcelone en Espagne. Elle est \u00e9galement dipl\u00f4m\u00e9e en immuno-oncologie de l’Institut Gustave Roussy \u00e0 Paris.\n\n\u00ab\u00a0Alors que nous entamons notre transformation d\u2019une entreprise de R&D vers une organisation commerciale, la vaste exp\u00e9rience d\u2019Elsy dans l\u2019industrie pharmaceutique et dans la strat\u00e9gie d\u2019entreprise repr\u00e9sente une contribution majeure \u00e0 la croissance de GenSight, \u00bb commente<\/em> Bernard Gilly<\/strong>, Co-fondateur et Directeur G\u00e9n\u00e9ral de GenSight Biologics. \u00ab\u00a0Je saisis l\u2019opportunit\u00e9 pour remercier Bpifrance Participations pour son soutien dans l\u2019aventure depuis l’introduction en bourse jusqu\u2019au d\u00e9p\u00f4t r\u00e9glementaire europ\u00e9en de LUMEVOQ.\u00a0\u00bb<\/em>\n\n \n

\u00c0 propos de GenSight\u00a0Biologics<\/strong><\/h3>\nGenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates-formes technologiques : le ciblage mitochondrial (Mitochondrial Targeting Sequence<\/em>, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. Le candidat m\u00e9dicament le plus avanc\u00e9 de GenSight Biologics, LUMEVOQ\u00ae<\/sup> (GS010 ; lenadogene nolparvovec), a fait l\u2019objet d\u2019un d\u00e9p\u00f4t de demande d\u2019AMM en Europe pour le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), une maladie mitochondriale rare affectant principalement les adolescents et les jeunes adultes et conduisant \u00e0 une perte irr\u00e9versible de la vue. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intra-vitr\u00e9enne dans chaque \u0153il.\n","protected":false},"excerpt":{"rendered":"

Paris, France, le 14 octobre 2020, 7h30 CEST \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN\u00a0: FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui\u00a0la nomination d\u2019Elsy Boglioli \u00e0 son Conseil d\u2019administration, en remplacement […]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[],"news-type":[],"post-year":[],"class_list":["post-3610","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers"],"acf":[],"yoast_head":"\nGenSight Biologics nomme Elsy Boglioli \u00e0 son Conseil d\u2019administration - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/14\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics nomme Elsy Boglioli \u00e0 son Conseil d\u2019administration - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 14 octobre 2020, 7h30 CEST \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN\u00a0: FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui\u00a0la nomination d\u2019Elsy Boglioli \u00e0 son Conseil d\u2019administration, en remplacement […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/14\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2020-10-14T09:30:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:08:39+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/10\\\/14\\\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/10\\\/14\\\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"GenSight Biologics nomme Elsy Boglioli \u00e0 son Conseil d\u2019administration\",\"datePublished\":\"2020-10-14T09:30:40+00:00\",\"dateModified\":\"2026-09-24T04:08:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/10\\\/14\\\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\\\/\"},\"wordCount\":719,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/10\\\/14\\\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/10\\\/14\\\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\\\/\",\"name\":\"GenSight Biologics nomme Elsy Boglioli \u00e0 son Conseil d\u2019administration - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-10-14T09:30:40+00:00\",\"dateModified\":\"2026-09-24T04:08:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/10\\\/14\\\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/10\\\/14\\\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2020\\\/10\\\/14\\\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics nomme Elsy Boglioli \u00e0 son Conseil d\u2019administration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics nomme Elsy Boglioli \u00e0 son Conseil d\u2019administration - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/14\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics nomme Elsy Boglioli \u00e0 son Conseil d\u2019administration - GenSight Biologics","og_description":"Paris, France, le 14 octobre 2020, 7h30 CEST \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN\u00a0: FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui\u00a0la nomination d\u2019Elsy Boglioli \u00e0 son Conseil d\u2019administration, en remplacement […]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/14\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\/","og_site_name":"GenSight Biologics","article_published_time":"2020-10-14T09:30:40+00:00","article_modified_time":"2026-09-24T04:08:39+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/14\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/14\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"GenSight Biologics nomme Elsy Boglioli \u00e0 son Conseil d\u2019administration","datePublished":"2020-10-14T09:30:40+00:00","dateModified":"2026-09-24T04:08:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/14\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\/"},"wordCount":719,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/14\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/14\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\/","name":"GenSight Biologics nomme Elsy Boglioli \u00e0 son Conseil d\u2019administration - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2020-10-14T09:30:40+00:00","dateModified":"2026-09-24T04:08:39+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/14\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/14\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2020\/10\/14\/gensight-biologics-nomme-elsy-boglioli-a-son-conseil-dadministration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics nomme Elsy Boglioli \u00e0 son Conseil d\u2019administration"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3610","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3610"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3610\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3610"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3610"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3610"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3610"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3610"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3610"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3610"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}